Active Growth Fund

Portfolio Investment Entity

Monthly Fact Sheet as at 31 December 2021



Portfolio Managers



Ionathan Windust Portfolio Manager



William Curtayne Co-Portfolio Manager

The Fund rose 3.6% in December and finished the year up by 18.1%. Global share markets rose as investors looked past Omicron and focused on strong growth prospects in the United States and continued low interest rates. The Fund performed well generating returns in excess of the markets it invests, due to strong company selection.


Key positive performing companies during the month included NZ healthcare logistics company EBOS (+13.0%), Australian bio-technology company Neuren (+109.4%), US hospital company HCA (+14.1%), US health insurer Anthem (+14.4%) and US home builder Pulte (+14.6%). EBOS rose following the acquisition of medical devices distribution company LifeHealthcare which complements EBOS' current pharmacy. healthcare and logistics businesses. Neuren rose following the positive trial of its treatment for Rett Syndrome, a rare disease. Whilst a small holding in the Fund, we were pleased to be able to support a company which will have major benefits for its patients. HCA, Anthem and Pulte were re-rated as investors focus shifted to companies with attractive valuations.

The outlook for shares in 2022 is supported by the prospect of strong economic growth, strong company earnings, low short-term interest rates and high levels of liquidity. The key headwinds for markets are relatively high valuations, generally optimistic investor sentiment and the prospect of rising inflation and interest rates. The prospect of rising Omicron cases may also cause short-term economic weakness. Whilst parts of the market have relatively full valuations, we continue to find companies which we believe are attractively valued. The strategy of the Fund is to remain active and construct a portfolio of investments which provide attractive medium-term risk adjusted returns.

To view Milford's January 2022 Market and Economic Review please see milfordasset.com/fact-sheet.

Cumulative Fund Performance

(after fees and before tax)



Assumes the growth of \$10,000 invested at the Fund's inception date.

Key Fund Facts

| Objective ¹ | To provide annual returns of 10% over the |
|------------------------|---|
| | minimum recommended investment timeframe |

Diversified fund that primarily invests in equities, with a moderate allocation to fixed interest Description

| Securitie | .5 | | | |
|--|---|--|--|--|
| Minimum recommended investment timeframe | 7 years + | | | |
| Target Allocation | 22% Income Assets / 78% Growth Assets | | | |
| Neutral FX Exposure | 16.0% | | | |
| Net Asset Value (NAV) | \$2,465.8 M | | | |
| Buy-sell Spread | None - swing pricing applies (See PDS for details) | | | |
| Inception Date | 1 October 2007 | | | |
| Benchmark | 10% p.a. | | | |
| Base Fund Fee ² | 1.05% | | | |
| Performance Fee | 15% of the Fund's returns above the Benchmark ¹ , subject to the high watermark. | | | |
| Total Fund Fees ³ | 1.25% (includes an est. performance fee) | | | |
| L | ower risk Higher risk | | | |
| Risk Indicator | 1 2 3 4 5 6 7 | | | |

Risk Indicator

Potentially lower returns

Potentially higher returns

External Ratings



Milford Active Growth Fund received a Morningstar Analyst Rating™ of 'Silver' on 07-07-2020



Unit Price: \$5.2606

Investment Performance after fees as at 31 December 2021⁴

| | 1 Month | 3 Months | 1 year | 3 years (p.a.) | 5 years (p.a.) | Since inception (p.a.) |
|--|---------|----------|--------|----------------|----------------|------------------------|
| Milford Active Growth Fund (Gross Of Tax) | 3.59% | 3.23% | 18.12% | 16.32% | 12.97% | 12.93% |
| After Tax 10.50% | 3.56% | 3.21% | 17.96% | 16.03% | 12.67% | 12.43% |
| After Tax 17.50% | 3.54% | 3.19% | 17.85% | 15.84% | 12.47% | 12.23% |
| After Tax 28.00% | 3.51% | 3.17% | 17.69% | 15.56% | 12.17% | 11.83% |
| Benchmark | 0.81% | 2.43% | 10.00% | 10.00% | 10.00% | 10.00% |

Top Equity Holdings

| Holdings | % of Fund |
|-----------------|-----------|
| Contact Energy | 3.42% |
| Virgin Money | 2.80% |
| Alphabet | 2.43% |
| Fisher & Paykel | 2.21% |
| Santos | 2.03% |
| Dr Horton | 1.95% |
| CRH | 1.94% |
| HCA Holdings | 1.89% |
| EBOS Group | 1.78% |
| Microsoft | 1.74% |

Top Fixed Interest Holdings

| Holdings | % of Fund |
|-------------------------------|-----------|
| ING Groep 4.25% Perpetual | 1.41% |
| JPMorgan 5% 2024 | 1.28% |
| Westpac 5% 2027 | 1.28% |
| Barclays 4.375% Perpetual | 1.01% |
| NatWest 5.125% Perpetual | 0.85% |
| Scentre Group 5.125% 2080 | 0.77% |
| Barclays 5.875% 2024 | 0.51% |
| Bank of Queensland Float 2032 | 0.46% |
| NatWest 6% Perpetual | 0.40% |
| Lloyds Bank 5.125% Perpetual | 0.36% |


Note: Fixed interest securities are reported in the following format: Issuer name, interest (coupon rate), maturity year.

Current Asset Allocation

| | Actual Investment Mix | Neutral Investment Mix |
|------------------------------|--------------------------|---------------------------|
| Effective Cash# | 8.16% | 6.0% |
| New Zealand Fixed Interest | 0.89% | 2.0% |
| International Fixed Interest | 11.22% | 14.0% |
| New Zealand Equities | 18.52% | 20.0% |
| Australian Equities | 20.54% | 18.0% |
| International Equities | 40.67% | 40.0% |
| Other | 0.00% | 0.0% |

[#] The actual cash held by the Fund is 8.53%. Effective Cash reported above is adjusted to reflect the Fund's notional positions (e.g. derivatives used to increase or reduce market exposure).

Fund Portfolio Mix



^{1.} After the base fund fee but before tax and before the performance fee. 2. Where applicable, the Base Fund Fee includes an estimate of non-related underlying fund charges. 3. The Total Fund Fees comprise the Base Fund Fee and any estimated Performance Fee. Please refer to the Product Disclosure Statement for more information as to how these are calculated. 4. Please note past performance is not a guarantee of future returns.